sub:assertion { d:DB05484v:identifier "DB05484" ; v:namespace "drugbank" ; v:uri "http://bio2rdf.org/drugbank:DB05484" ; v:x-identifiers.org <http://identifiers.org/drugbank/DB05484> ; dv:drugbank-id "DB05484" ; dv:x-cas <http://bio2rdf.org/cas:> ; dct:description "MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD) and pustular dermatoses. In pre-clinical studies, HuMax-Inflam has been shown to inhibit tumor growth in tumor models using primary human tumors in immunodeficient mice. HuMax-Inflam was also effective in reducing disease activity in palmoplantar pustulosis patients in a clinical study."@en ; dct:identifier "drugbank:DB05484" ; dct:title "MDX-018"@en ; adv:Drug ; rdfs:label "MDX-018 [drugbank:DB05484]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05484> . }